PubMed HealthSearch

Biomedical subjects

Y Kojima

Publications and source records attributed to Y Kojima.

At least 19 recordsLinked to original sources

Metallothionein: an exceptional metal thiolate protein.

Metallothioneins are unusual, low molecular weight proteins of extremely high sulphur and metabl content. They occur in substantial quantity and in multiple variant forms in parenchymatous tissues (liver, kidney, intestines) of vertebrates and certain microorganisms (Neurospora crassa, yeast). They are though to play a central role in the cellular metabolism of metals such as zinc, copper and cadmium. All mammalian forms studied are single chains with 20 cysteinyl residues among a total of 61 amino acid residues and highly characteristic amino acid sequences. Their most conspicuous common features are seven -Cys-X-Cys- sequences where X stands for an alphatic residue other than Cys. Together with additional cysteinyl residues located elsewhere in the chain and brought into juxtaposition by appropriate chain folding, these dithiol sequences are believed to form the basis of the trithiolate chelating structures typical of most of the six or seven metal-binding sites of the mammalian cadium- and/or zinc-containing metallothioneins. The positions of the cysteinyl residues are preserved in evolution: the copper-containing metallothionein from Neurospora crassa, containing only 25 amino acid residues, has a distribution of metal-binding cysteinyl residues identical to that of the N-terminal portion of the mammalian chains. The detailed physiological role of metallothionein remains to be clarified but its biosynthesis is known to be modulated by nutritional and endocrine factors. Recent evidence suggests that metallothionein is a critical determinant in the homeostasis of zinc.

Amino Acid Sequence

Regions of the lipopolysaccharide of Pseudomonas aeruginosa essential for antitumor and interferon-inducing activities.

Resistance against ascites tumor development and interferon-inducing activity were demonstrated in lipopolysaccharide derived from the protein-lipopolysaccharide complex obtained from an autolysate of Pseudomonas aeruginosa. Lipid A obtained from the lipopolysaccharide was sufficient to induce interferon in vitro but no antitumor activity was found if lipid A or the polysaccharide derived from lipopolysaccharide was injected into the animal. Chemical modification of the polysaccharide portion or deacylation of the lipopolysaccharide also diminished antitumor activity. In contrast, interferon was induced by these incomplete lipopolysaccharides. These results indicate that both the lipid A portion and covalently linked polysaccharide are necessary for the inhibition of ascites tumor development, whereas incomplete lipid A with amide-linked fatty acids is sufficient to induce interferon in vitro.

Amino Acids

The pharmacology of 20681-S and 20682-S, 6-oxo-N-cyclopropylmethylmorphinans, as narcotic antagonist analgesics.

It has been demonstrated that L-3hydroxy-6-oxo-N-cyclopropylmethylmorphinan methansulfonate (20681-S) and L-3,14-dihydroxy-6-oxo-N-cyclopropylmethylmorphinan methansulfonate (20682-S), have antinociceptive and narcotic antagonistic properties. In the rodent antinociceptive test, the action of 20681-S was more potent and of longer duration than that of morphine and of cyclazocine after subcutaneous or oral administration. The antinociceptive effect of 20682-S ranked between that of morphine and that of pentazocine in the mouse acetic acid-writhing test. Both compounds possessed potent narcotic antagonistic activities, 20682-S being more active than naloxone and oxilorphan and 20681-S being equipotent with cyclazocine. The latent side effects (respiratory depression and fall in blood pressure) and the acute toxicity of 20681-S and 20682-S, were less than those of reference narcotic antagonists or of narcotic antagonist analgesics.

Analgesics